TrialInfection2019

A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults.

Micha Loebermann et al.PubMed ↗Publisher ↗

No numbers read from the abstract.